Effect of Age and Prior Immunity to Response to Seasonal Influenza Vaccines in Children [clinicaltrials:NCT01246999]

Bio2RDF identifier

NCT01246999

http://www.w3.org/2001/XMLSchema#string

Bio2RDF namespace

clinicaltrials

http://www.w3.org/2001/XMLSchema#string

Bio2RDF uri

http://bio2rdf.org/clinicaltrials:NCT01246999

http://www.w3.org/2001/XMLSchema#string

identifiers.org URI

NCT01246999

anticipated enrollment [clinicaltrials_vocabulary:anticipated-enrollment]

88

http://www.w3.org/2001/XMLSchema#integer

arm group [clinicaltrials_vocabulary:arm-group]

NCT01246999 arm group 17b5617a2288ee3e78d6e877987bccc4 [clinicaltrials_resource:NCT01246999/arm-group/17b5617a2288ee3e78d6e877987bccc4]

NCT01246999 arm group 2bf4c8767330406bc003457949e1f1bb [clinicaltrials_resource:NCT01246999/arm-group/2bf4c8767330406bc003457949e1f1bb]

NCT01246999 arm group 771739520768f9401fec79fc021a7d43 [clinicaltrials_resource:NCT01246999/arm-group/771739520768f9401fec79fc021a7d43]

NCT01246999 arm group 8739ae7ca05b5f6f484ed4810ab45351 [clinicaltrials_resource:NCT01246999/arm-group/8739ae7ca05b5f6f484ed4810ab45351]

authority [clinicaltrials_vocabulary:authority]

clinicaltrials_resource:ca1954f55de6b13c270f49787460e895

brief summary [clinicaltrials_vocabulary:brief-summary]

A total of 88 children ...... 1 infection will be excluded.

http://www.w3.org/2001/XMLSchema#string

brief title [clinicaltrials_vocabulary:brief-title]

Effect of Age and Prior Immunity to Response to Seasonal Influenza Vaccines in Children

http://www.w3.org/2001/XMLSchema#string

clinicaltrials_vocabulary:primary outcome [clinicaltrials_vocabulary:clinicaltrials_vocabulary:primary-outcome]

The primary end point for assessment of live attenuated vaccine take will be the AUC of nasopharyngeal strain-specific virus assessed by immunoperoxidase stained plaquesin MDCK cells at 33 degrees C nasal swabs obtained at day 2 post vacination [clinicaltrials_resource:b67c39062ee231795eaedf8b6c9cab6c]

The primary end point for assessment of live attenuated vaccine take will be the AUC of nasopharyngeal strain-specific virus assessed by immunoperoxidase stained plaquesin MDCK cells at 33 degrees C nasal swabs obtained at day 2 post vacination [clinicaltrials_resource:b87d36505a81bdf7821bf3229171f7f6]

The primary end point for assessment of live attenuated vaccine take will be the AUC of nasopharyngeal strain-specific virus assessed by immunoperoxidase stained plaquesin MDCK cells at 33 degrees C nasal swabs obtained at day 2 post vacination [clinicaltrials_resource:c79fd082c0144c3eabb2eb21333c7cdc]

clinicaltrials_vocabulary:secondary outcome [clinicaltrials_vocabulary:clinicaltrials_vocabulary:secondary-outcome]

The primary end point for assessment of live attenuated vaccine take will be the AUC of nasopharyngeal strain-specific virus assessed by immunoperoxidase stained plaquesin MDCK cells at 33 degrees C nasal swabs obtained at day 2 post vacination [clinicaltrials_resource:4f8182a3efbc8fde5f78839283fe11e9]

The primary end point for assessment of live attenuated vaccine take will be the AUC of nasopharyngeal strain-specific virus assessed by immunoperoxidase stained plaquesin MDCK cells at 33 degrees C nasal swabs obtained at day 2 post vacination [clinicaltrials_resource:86be85abe0656fa0310d1ec45ab33e80]

The primary end point for assessment of live attenuated vaccine take will be the AUC of nasopharyngeal strain-specific virus assessed by immunoperoxidase stained plaquesin MDCK cells at 33 degrees C nasal swabs obtained at day 2 post vacination [clinicaltrials_resource:8ce180685b10cf64f76c8c94061d107c]

The primary end point for assessment of live attenuated vaccine take will be the AUC of nasopharyngeal strain-specific virus assessed by immunoperoxidase stained plaquesin MDCK cells at 33 degrees C nasal swabs obtained at day 2 post vacination [clinicaltrials_resource:a4cf9d03a7ce94ca10a08d3f3c5d2160]

The primary end point for assessment of live attenuated vaccine take will be the AUC of nasopharyngeal strain-specific virus assessed by immunoperoxidase stained plaquesin MDCK cells at 33 degrees C nasal swabs obtained at day 2 post vacination [clinicaltrials_resource:ad0cc2916613ba84401627d938c9d1cc]

The primary end point for assessment of live attenuated vaccine take will be the AUC of nasopharyngeal strain-specific virus assessed by immunoperoxidase stained plaquesin MDCK cells at 33 degrees C nasal swabs obtained at day 2 post vacination [clinicaltrials_resource:b70e5f791833a6c5ff8a4b5005232e24]

collaborator [clinicaltrials_vocabulary:collaborator]

University of Rochester [clinicaltrials_resource:a2ee82f5298e76bec3e878b4f0918a4f]

completion date [clinicaltrials_vocabulary:completion-date]

2012-04-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

detailed description [clinicaltrials_vocabulary:detailed-description]

The study will be condu ...... d TCID50 on MDCK cells.

http://www.w3.org/2001/XMLSchema#string

download date [clinicaltrials_vocabulary:download-date]

ClinicalTrials.gov processed this data on August 10, 2015

http://www.w3.org/2001/XMLSchema#string

eligibility [clinicaltrials_vocabulary:eligibility]

eligibility for clinicaltrials:NCT01246999 [clinicaltrials_resource:e29f4ab68718f4556bac3cedd8f38f76]

firstreceived date [clinicaltrials_vocabulary:firstreceived-date]

2010-11-22T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

has expanded access [clinicaltrials_vocabulary:has-expanded-access]

No

http://www.w3.org/2001/XMLSchema#string

intervention [clinicaltrials_vocabulary:intervention]

Seasonal Trivalent Influenza Vaccine 2010-2011 [clinicaltrials_resource:1af31a91f2fd587015245f21ee7d78f4]

Seasonal Influenza Vaccine TIV/LAIV [clinicaltrials_resource:3d753e170adf352aacf23467eb921420]

Trivalent Seasonal Live attenuated Influenza vaccine [clinicaltrials_resource:8386f12f4694d661d4d3fada596e8dec]

Seasonal Influenza Vaccines LAIV/TIV [clinicaltrials_resource:c3b366902e1f3cc1eadcde6aff9f7e15]

is fda regulated [clinicaltrials_vocabulary:is-fda-regulated]

Yes

http://www.w3.org/2001/XMLSchema#string

is section 801 [clinicaltrials_vocabulary:is-section-801]

Yes

http://www.w3.org/2001/XMLSchema#string

keyword [clinicaltrials_vocabulary:keyword]

A/California/7/2009-like (2009 H1N1)

http://www.w3.org/2001/XMLSchema#string

A/Perth/16/2009-like (H3N2)

http://www.w3.org/2001/XMLSchema#string

B/Brisbane/60/2008-like (B/Victoria lineage)

http://www.w3.org/2001/XMLSchema#string

Influenza

http://www.w3.org/2001/XMLSchema#string

lastchanged date [clinicaltrials_vocabulary:lastchanged-date]

2011-08-02T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

lead sponsor [clinicaltrials_vocabulary:lead-sponsor]

University of Rochester [clinicaltrials_resource:a2ee82f5298e76bec3e878b4f0918a4f]

location [clinicaltrials_vocabulary:location]

Dartmouth-Hitchcock Medical Center [clinicaltrials_resource:58c76b78e59150f2c5ca801df636fdfa]

nct id [clinicaltrials_vocabulary:nct-id]

NCT01246999

http://www.w3.org/2001/XMLSchema#string

number of arms [clinicaltrials_vocabulary:number-of-arms]

4

http://www.w3.org/2001/XMLSchema#integer

official title [clinicaltrials_vocabulary:official-title]

Evaluation of the Effect of Ag ...... Influenza Vaccines in Children

http://www.w3.org/2001/XMLSchema#string

org study id [clinicaltrials_vocabulary:org-study-id]

URMC10-005/Dartmouth 22164

http://www.w3.org/2001/XMLSchema#string

overall status [clinicaltrials_vocabulary:overall-status]

Active, not recruiting [clinicaltrials_resource:a6bc1606956390bcd6a391faced78809]

oversight [clinicaltrials_vocabulary:oversight]

United States: Institutional Review Board [clinicaltrials_resource:b46c5f1ee626ee51e33e6c048a7b19f6]

phase [clinicaltrials_vocabulary:phase]

Phase 4 [clinicaltrials_resource:ec41833bc88cd90619c4d85c549688bd]

primary completion date [clinicaltrials_vocabulary:primary-completion-date]

2012-04-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

reference [clinicaltrials_vocabulary:reference]

10501238 [pubmed:10501238]

16971435 [pubmed:16971435]

17050593 [pubmed:17050593]

17301299 [pubmed:17301299]

19423871 [pubmed:19423871]

19745214 [pubmed:19745214]

19745216 [pubmed:19745216]

5773321 [pubmed:5773321]

6997969 [pubmed:6997969]

7975853 [pubmed:7975853]

responsible party [clinicaltrials_vocabulary:responsible-party]

John J. Treanor, MD, Department of Internal Medicine, Division of Infectious Diseases, University of Rochester Medical Center [clinicaltrials_resource:64dbf546a548a238cd22d6247a7d4eda]

source [clinicaltrials_vocabulary:source]

University of Rochester [clinicaltrials_resource:a2ee82f5298e76bec3e878b4f0918a4f]

start date [clinicaltrials_vocabulary:start-date]

2010-10-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

study design [clinicaltrials_vocabulary:study-design]

clinicaltrials:NCT01246999 study design [clinicaltrials_resource:45cb7c3a52bb4f7eb448330518bbbdca]

study type [clinicaltrials_vocabulary:study-type]

Interventional [clinicaltrials_resource:843ac00ae5d0b7c7defb84fb42c2ce31]

url [clinicaltrials_vocabulary:url]

NCT01246999

verification date [clinicaltrials_vocabulary:verification-date]

2010-11-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

identifier

clinicaltrials:NCT01246999

http://www.w3.org/2001/XMLSchema#string

title

Effect of Age and Prior Immunity to Response to Seasonal Influenza Vaccines in Children

@en

inDataset

clinicaltrials_resource:bio2rdf.dataset.clinicaltrials.R3

type

Clinical Study [clinicaltrials_vocabulary:Clinical-Study]

clinicaltrials resource [clinicaltrials_vocabulary:Resource]

label

Effect of Age and Prior Immuni ...... n [clinicaltrials:NCT01246999]

@en